Shots:
- AstraZeneca announced that tozorakimab met the 1EP in the P-III (MIRANDA) study, significantly reducing annualised rate of moderate-to-severe COPD exacerbations across pts. with COPD that still experiencing exacerbations while on inhaled SoC
- In study pts. (n=1,454) received tozorakimab 300mg or PBO on top of SoC once every two weeks, including former and current smokers, regardless of eosinophil levels or lung function severity
- MIRANDA marks the third positive P-III study, reinforcing tozorakimab’s potential as a first-in-class biologic, with regulatory submissions anticipated
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News: AstraZeneca Reports the P-III (EMERALD-3) Trial Data on Imfinzi Combination + TACE in Unresectable Hepatocellular Carcinoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
